top of page
Ketamine Academy Blog
Search
Jason A. Duprat MBA, MSA, APRN, CRNA
16 hours ago2 min read
FDA Approves Spravato (Esketamine) as Standalone Treatment for Depression
The FDA has approved Spravato (esketamine) nasal spray as the first monotherapy for treatment-resistant depression (TRD)
Ketamine Academy
Oct 13, 20217 min read
Ketamine’s Cognitive Side Effects: Fact or Myth?
Its reputation as a club drug has raised red flags, but studies show that its effects on cognitive function are dose-dependent.
Ketamine Academy
Sep 9, 20218 min read
Perks, Planning, and People: Things Hindering Off-Patent Ketamine’s FDA Approval for Depression
Unlike esketamine nasal spray, the old formulation doesn’t have FDA approval for treating major depression & similar mental health problems.
Ketamine Academy
Aug 4, 20218 min read
Racemic Ketamine vs. Esketamine: What Is the Difference, and Why Is It Critical to Patient Care?
A quick guide on the chemical, clinical & pharmacological differences between intravenous racemic ketamine & intranasal ketamine.
bottom of page